MTOR and breast cancer: Taken together, these studies provide evidence that activation of AKT-signaling is an adverse prognostic factor in breast cancer and support the rational for normalizing insulin-driven PI3K/AKT/mTOR-signaling pathway in women with breast cancer and woman at risk for breast cancer.